448 related articles for article (PubMed ID: 22941898)
1. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
Morrissey I; Seifert H; Canton R; Nordmann P; Stefani S; Macgowan A; Janes R; Knight D;
J Antimicrob Chemother; 2013 Jan; 68(1):164-7. PubMed ID: 22941898
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
5. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE
Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
7. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
8. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
Bezian MC; Ribou G; Masquelier B
Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Arhin FF; Draghi DC; Pillar CM; Parr TR; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2009 Nov; 53(11):4762-71. PubMed ID: 19738026
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Sader HS; Streit JM; Fritsche TR; Jones RN
Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
Belley A; Harris R; Beveridge T; Parr T; Moeck G
Antimicrob Agents Chemother; 2009 Feb; 53(2):800-4. PubMed ID: 19029329
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP
Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
[TBL] [Abstract][Full Text] [Related]
16. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
Jansen WT; Verel A; Verhoef J; Milatovic D
Antimicrob Agents Chemother; 2007 Sep; 51(9):3420-4. PubMed ID: 17606689
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
20. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]